Business Wire

[Informing you about premier stocks before they hit Wall Street]

[ Business | US Market | Industry | IPO | S&P | International | PRNews | BizWire | Finance Home ]

Tuesday January 13, 8:24 am Eastern Time

Company Press Release

Autonomous Technologies Scheduled for FDA Panel Review in February

ORLANDO, Fla.--(BW HealthWire)--January 13, 1998--AUTONOMOUS TECHNOLOGIES CORPORATION (NASDAQ NM: ATCI - news) today announced that the Ophthalmic Devices Panel of the U.S. Food and Drug Administration (FDA) will review the Company's premarket approval application (PMA) for the Autonomous LADARVision(R) System on February 13, 1998. The PMA submission encompasses myopia with astigmatism of up to -10 diopters of myopic refractive error.

Commenting on the FDA's announcement, Randy Frey, President and CEO of Autonomous Technologies, stated, ``We look forward to supporting our compelling data at the FDA panel meeting in February. Our PMA team has worked effectively to put Autonomous in this strong position and I congratulate them for a job well done. As we approach the most important milestone of our Company's history, we are committed, as always, to providing superior technology and better results for a broader range of patients.''

The FDA Ophthalmic Advisory Panel reviews the PMA application for approvability. The FDA accepts the advice of the Panel, but is not necessarily bound by its decision.

Autonomous Technologies is engaged in the design and development of next-generation excimer laser instruments for laser refractive surgery. The Company's LADARVision System combines high speed, laser radar eye tracking with precisely controlled narrow beam shaping technology.

The statements in this press release which express belief, anticipation, or expectations, as well as other statements which are not historical fact, are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties that could cause actual results or performance of the Company to differ materially from the results or performance described herein. Please see the Company's filings with the Securities & Exchange Commission for a statement of certain risks and uncertainties.

     Autonomous Technologies
     Randy Frey
     (407) 384-1600

More Quotes and News:Autonomous Technologies Corp (Nasdaq:ATCI - news)
Related News Categories: biotech, government, medical/pharmaceutical

[ Yahoo! ]
Copyright © 1998 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina public database, redistributing via a computer network or in a printed form.
See our Important Disclaimers and Legal Information.
Questions or Comments?